|
KMID : 0370220210650020150
|
|
Yakhak Hoeji
2021 Volume.65 No. 2 p.150 ~ p.157
|
|
|
Analysis of the Expansion of the Reimbursement Coverage and Value-based Pricing for Anticancer Drugs in South Korea
|
|
Ha So-Young
Kang Dong-Won
Hwang In-Gyoung
Park Mi-Hai
|
|
|
Abstract
|
|
|
|
Anticancer drugs with multi-indications have recently increased, which creates the need for a new pricingsystem that reflects the value of each indication. This study aims to describe the current status of the expansion ofreimbursement coverage of anticancer drugs in Korea. Immunotherapy and targeted therapy were analyzed to find out thestatus of approval and listing. We identified the status of the expansion of reimbursement coverage and the price reductionrate. A survey was conducted with pharmaceutical employees to find their opinions on the current and newly suggestedpricing system. In South Korea, 54 anticancer drugs (four immunotherapy and 50 targeted therapy drugs) had beenreimbursed by April 2020. Three out of the four immunotherapy drugs (75.0%) and 29 of the 50 targeted therapy drugs(58.0%) were confirmed to have multi-indications. Among them, all four immunotherapy drugs and 25 (86.2%) of thetargeted therapy drugs had their reimbursement coverage expanded. The price reduction also stood out as the expansionof the reimbursement coverage increased. Most pharmaceutical employees had recognized a problem with the current drugpricing system and were aware of the need to improve it. Therefore, the drug pricing system needs to be changed to onethat reflects the value of the drug when the indication is expanded.
|
|
|
KEYWORD
|
|
|
Immunotherapy, anticancer drug, multi-indication, drug pricing, value-based pricing
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|